Peptide data sheet
Pemvidutide
GLP-1 · ALT-801
Verdict
promisingobesity / MASH (investigational, early human trials)
Quick answer
Pemvidutide (ALT-801) is an investigational GLP-1/glucagon dual receptor agonist developed by Altimmune. It is commonly researched for weight management and metabolic dysfunction-associated steatohepatitis (MASH), with early Phase 2 human trials reporting notable weight change. It is not FDA-approved, is not available for human use outside trials, and its longer-term safety and effects are still being studied.
- Class
- GLP-1 / glucagon dual receptor agonist
- Half-life
- supports once-weekly dosing (per developer reports)
- FDA status
- Not FDA-approved (investigational)
Which form actually works?
Investigational injectable (trial use)
Promising
The form studied in Altimmune's Phase 2 obesity and MASH programs. Early data has been reported by the sponsor; results have not been confirmed in large Phase 3 trials, and it is not available or approved for human use.
Gray-market vial
Risky
Any product sold as pemvidutide outside a clinical trial is unregulated. Purity, sterility, and labeled strength are unverified, and this is where the real supply-safety danger sits.